FindTrial
Sign In

ANGIOCOMB Antiangiogenetic therapy for pediatric patients with brain stem tumors - Angiocomb

ANGIOCOMB Antiangiogenetic therapy for pediatric patients with brain stem tumors - Angiocomb

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2005-004850-28-FI
Enrollment
Unknown
Registered
2005-10-20
Start date
2005-11-24
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Brain sten tumor

Interventions

Trade Name: Thalix Pharmaceutical Form: Tablet INN or Proposed INN: thalidomid Trade Name: Celebra Pharmaceutical Form: Tablet INN or Proposed INN: selekoksibi Trade Name: Etoposide Pharmaceutical F

Sponsors

Hospital for Children and Adolescents
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? yes Number of subjects for this age range: F.1.2 Adults (18-64 years) no F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Main Objective: ;Secondary Objective: ;Primary end point(s):—

Countries

Finland

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026